Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis

被引:0
|
作者
Mansuri, Zeeshan [1 ]
Ashraf, Hadiah [2 ]
Taikadan, Thahsin [3 ]
Rajith, Gokul [4 ]
Ayesha, Ayesha [5 ]
Fatima, Urooj [6 ]
Erzinger, Gabriel [7 ]
机构
[1] GCS Med Coll & Res Ctr, Dept Cardiol, Opp DRM Off,Naroda Rd, Ahmadabad 380025, Gujarat, India
[2] Rawalpindi Med Univ, Rawalpindi, Pakistan
[3] Calicut Med Coll, Kozhikode, India
[4] All India Inst Med Sci, Gauhati, India
[5] Shifa Coll Med, Islamabad, Pakistan
[6] Jinnah Sindh Med Univ, Karachi, Pakistan
[7] Univ Joinville Reg UNIVILLE, Joinville, Brazil
关键词
dual anti-platelet therapy; percutaneous coronary intervention; ticagrelor; ASPIRIN;
D O I
10.1097/MCA.0000000000001417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The optimum duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) remains controversial. Ticagrelor monotherapy after short duration of DAPT (1-3 months) is a subject of research. We conducted an updated systematic review and meta-analysis comparing the ticagrelor monotherapy with continued DAPT after short duration of DAPT in patients with ACS undergoing PCI. Methods PubMed, Embase, and Cochrane databases were searched for studies comparing ticagrelor monotherapy to DAPT after PCI and reported the outcomes of major adverse cardiovascular and cerebrovascular events (MACCE); net adverse clinical events (NACE); myocardial infarction (MI); major bleeding; death from any cause; definite or probable stent thrombosis; and target vessel revascularization (TVR). Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Statistical analysis was performed using Review Manager (Cochrane collaboration). Heterogeneity was examined with I-2 test. Results Of 3,208 results, five studies with 21,407 patients were included of which 50% received ticagrelor monotherapy. Studies had reported follow up of 12 months. Major bleeding [hazard ratio 0.47; 95% confidence interval (CI), 0.37-0.61; P < 0.001], NACE (hazard ratio 0.71; 95% CI, 0.56-0.90; P = 0.005), and all-cause death (hazard ratio 0.76; 95% CI, 0.59-0.98; P = 0.04) were significantly less with ticagrelor monotherapy. Other outcomes were comparable in both groups. Conclusion In patients with ACS undergoing PCI, ticagrelor monotherapy reduces major bleeding, NACE and all-cause death as compared to continued DAPT for 12 months. Major ischemic outcomes were similar. Ticagrelor monotherapy is the way forward after short duration of DAPT after PCI in ACS.
引用
收藏
页码:590 / 597
页数:8
相关论文
共 50 条
  • [41] Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
    Condello, Francesco
    Sturla, Matteo
    Terzi, Riccardo
    Polimeni, Alberto
    Stefanini, Giulio G.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [42] Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials
    Ning, Chen
    Ling, Fang
    Liu, Deyi
    Zhi, Zhang
    BMC CARDIOVASCULAR DISORDERS, 2024, 24 (01)
  • [43] Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials
    Chen Ning
    Fang Ling
    Deyi Liu
    Zhang Zhi
    BMC Cardiovascular Disorders, 24
  • [44] Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis
    Zhang, Junyan
    Chen, Zhongxiu
    Li, Chen
    Wang, Duolao
    He, Siyu
    Luo, Chaoyu
    Luo, Fangbo
    He, Yong
    CORONARY ARTERY DISEASE, 2022, 33 (07) : 580 - 589
  • [45] TRIPLE VERSUS DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
    Hu, Bin
    Zhou, Yujie
    Liu, Yuyang
    Shi, Dongmei
    Zhao, Yingxin
    Jia, Dean
    HEART, 2010, 96 : A107 - A107
  • [46] Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis
    Palmerini, Tullio
    Bruno, Antonio Giulio
    Gasparini, Mauro
    Rizzello, Giulia
    Kim, Hyo-Soo
    Kang, Jeehoon
    Park, Kyung-Woo
    Hahn, Joo-Yong
    Song, Young Bin
    Gwon, Hyeon-Cheol
    Choo, Eun Ho
    Park, Mahn-Won
    Kim, Chan Joon
    Chang, Kiyuk
    Cuisset, Thomas
    Taglieri, Nevio
    Kim, Byeong-Keuk
    Jang, Yangsoo
    Nardi, Elena
    Saia, Francesco
    Orzalkiewicz, Matheusz
    Chietera, Francesco
    Ghetti, Gabriele
    Galie, Nazzareno
    Stone, Gregg W.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2022, 15 (11) : 906 - 914
  • [47] Bleeding versus ischemic risk during dual antiplatelet therapy on patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Nau, Gerardo
    Lalor, Nicolas
    Pedernera, Gustavo
    Daquarti, Gustavo
    Spaletra, Pablo
    Candiello, Alfonsina
    Padilla, Lucio
    Trivi, Marcelo
    Cura, Fernando
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2016, 45 (02): : 67 - 72
  • [48] Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis
    Geng, Xue
    Zhang, Ya-Nan
    Cui, Wei
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (04)
  • [49] Oral antithrombotic therapy after acute coronary syndromes: "dual antiplatelet" or "dual pathway"?
    Capodanno, Davide
    EUROINTERVENTION, 2017, 13 (07) : 773 - 775
  • [50] Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: Insights From a Network Meta-Analysis of Randomized Trials
    Kuno, Toshiki
    Ueyama, Hiroki
    Takagi, Hisato
    Fox, John
    Bangalore, Sripal
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (17) : B109 - B110